ReviewAllergology international : official journal of the Japanese Society of Allergology2015
Immunopathology of chronic rhinosinusitis.
Review in Allergology international : official journal of the Japanese Society of Allergology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
141 citing papers in PubMed, 2 syntheses or guidelines pooled it, 273 citations in OpenAlex.
- Correlation of Local Nasal Biomarkers and Olfactory Dysfunction in Chronic Rhinosinusitis: A Systematic Review and Meta-Analysis.International forum of allergy & rhinology · 2026Pooled it
- Prevalence and risk factors of chronic rhinosinusitis among Chinese: A systematic review and meta-analysis.Frontiers in public health · 2022Pooled it
- Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results.The Annals of otology, rhinology, and laryngology · 2023Trial
- Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps.International forum of allergy & rhinology · 2021Trial
- Heterogeneous inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois.The Journal of allergy and clinical immunology · 2017Trial
- From Inflammation to Tissue State: A Compartment Model for Chronic Rhinosinusitis.Clinical and translational allergy · 2026Article
- Immune Clues to Sinus Blues: Linking Biomarkers to Radiologic Score of Rhinosinusitis.World journal of otorhinolaryngology - head and neck surgery · 2026Article
- Predictive value of blood eosinophil count and serum total immunoglobulin E for type 2 chronic rhinosinusitis according to allergic sensitization status.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Responses of Nasal Polyp-Derived Macrophages to Inflammatory Cues and Potential Pathological Roles in Type 2 Chronic Rhinosinusitis With Nasal Polyps.Clinical and experimental otorhinolaryngology · 2026Article
- Uncovering Cystic Fibrosis Carrier: Insights From a Heterozygous CFTR-F508del Rabbit Model.International forum of allergy & rhinology · 2026Article
- Olfactory Bulb Volume and Function Recovery in Eosinophilic Chronic Rhinosinusitis.The Laryngoscope · 2026Observational
- Chronic Rhinosinusitis at the Interface of Type 2 Inflammation, Epithelial Barrier Dysfunction, and Microbiome Dysbiosis.Microorganisms · 2026Review
- Real-world sinonasal outcomes in patients with primary diffuse chronic rhinosinusitis treated with mepolizumab across polyp phenotypes.Frontiers in immunology · 2026Article
- Biological Sex and Chronic Rhinosinusitis Diagnosis and Biomarkers.JAMA otolaryngology-- head & neck surgery · 2026Article
- The molecular mechanism of circRNA_0021727 in inflammation of eosinophilic chronic rhinosinusitis.Frontiers in immunology · 2026Article
- Article
- Epithelial Lining Fluid Cystatin SN is a Noninvasive Biomarker for Predicting Type 2 Chronic Rhinosinusitis.Allergy · 2025Article
- Effectiveness of dupilumab in chronic rhinosinusitis with nasal polyps: A retrospective study of clinical and imaging outcomes.Saudi medical journal · 2025Article
- Blood IgE and Eosinophils are not Reliable Predictors of Nasal Tissue Eosinophils in Chronic Rhinosinusitis with Nasal Polyposis.International archives of otorhinolaryngology · 2025Article
- Systemic barrier dysfunction in type 2 inflammation diseases: perspective in the skin, airways, and gastrointestinal tract.Immunologic research · 2025Review
81 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Chronic rhinosinusitis (CRS) is a heterogeneous disease characterized by local inflammation of the upper airways and sinuses which persists for at least 12 weeks. CRS can be divided into two phenotypes dependent on the presence of nasal polyps (NPs); CRS with NPs (CRSwNP) and CRS without NPs (CRSsNP). Immunological patterns in the two diseases are known to be different. Inflammation in CRSsNP is rarely investigated and limited studies show that CRSsNP is characterized by type 1 inflammation. Inflammation in CRSwNP is well investigated and CRSwNP in Western countries shows type 2 inflammation and eosinophilia in NPs. In contrast, mixed inflammatory patterns are found in CRSwNP in Asia and the ratio of eosinophilic NPs and non-eosinophilic NPs is almost 50:50 in these countries. Inflammation in eosinophilic NPs is mainly controlled by type 2 cytokines, IL-5 and IL-13, which can be produced from several immune cells including Th2 cells, mast cells and group 2 innate lymphoid cells (ILC2s) that are all elevated in eosinophilic NPs. IL-5 strongly induces eosinophilia. IL-13 activates macrophages, B cells and epithelial cells to induce recruitment of eosinophils and Th2 cells, IgE mediated reactions and remodeling. Epithelial derived cytokines, TSLP, IL-33 and IL-1 can directly and indirectly control type 2 cytokine production from these cells in eosinophilic NPs. Recent clinical trials showed the beneficial effect on eosinophilic NPs and/or asthma by monoclonal antibodies against IL-5, IL-4Rα, IgE and TSLP suggesting that they can be therapeutic targets for eosinophilic CRSwNP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.